Cellular Biomedicine Group Inc. announced that it has entered into a global collaboration and licensing agreement with Janssen Biotech Inc. to develop and commercialize Non-Hodgkin lymphoma drugs. Cellular Biomedicine will receive $245 million in upfront payments and milestone payments upon certain clinical development and sales achievements. Rockville, Maryland-based Cellular Biomedicine was advised by a Davis Polk & Wardwell team that included partner David R. Bauer. Counsel information for Janssen Biotech, which is based in Montgomery County, Pennsylvania, was not immediately available.